Hutchmed (China) (00013) announced that on August 5, 2024, the company has granted the stock options under the stock options plan adopted by Hutchmed in 2015 and the rewards under the long-term incentive plan adopted by Hutchmed in 2015.
Hutchmed granted its stock options under the stock option plan to Wei Guo Su (Executive Director, CEO and Chief Scientific Officer), who is the person responsible for regulatory compliance in accordance with the Market Abuse Regulation in the UK, subject to performance targets; Upon acceptance by the grantee, for the purchase of a total of 1.4058 million shares of common stock with a par value of $0.10 per share in the company.
Hutchmed granted its stock options under the stock option plan to one of its employees, subject to acceptance by the grantee, for the purchase of a total of 0.2 million shares of common stock in the company.